XSpray Pharma AB Market Cap ($59.70 Million)
Market Cap & Net Worth: XSpray Pharma AB (XSPRAY)
XSpray Pharma AB market cap. XSpray Pharma AB (ST:XSPRAY) has a market capitalization of $59.70 Million (Skr554.77 Million) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #21017 globally and #377 in its home market, demonstrating a 13.37% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying XSpray Pharma AB's stock price Skr11.70 by its total outstanding shares 47416574 (47.42 Million). Also see XSpray Pharma AB (XSPRAY) cash flow conversion for how efficiently the company converts equity into cash flow.
XSpray Pharma AB Market Cap History (2017–2026)
XSpray Pharma AB market cap history from 2017 to 2026. Data shows change from $317.65 Million to $59.70 Million (-10.28% CAGR). Check XSPRAY stock price and chart for real-time trading data and today's change.
XSpray Pharma AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how XSpray Pharma AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of XSpray Pharma AB to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1296.88x
XSpray Pharma AB's market cap is 1296.88 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $317.65 Million | $331.55K | -$13.20 Million | 958.08x | N/A |
| 2018 | $359.24 Million | $277.00K | -$23.10 Million | 1296.88x | N/A |
Competitor Companies of XSPRAY by Market Capitalization
Companies near XSpray Pharma AB in the global market cap rankings as of November 4, 2026. Also see XSpray Pharma AB total assets for a full breakdown of the balance sheet.
Key companies related to XSpray Pharma AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of XSpray Pharma AB (2017–2026)
Market capitalization of XSpray Pharma AB from 2017 to today. Between 2017 and today, XSpray Pharma AB's market cap moved from $317.65 Million to $ 59.70 Million, with a yearly change of -10.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr59.70 Million | -62.80% |
| 2025 | Skr160.48 Million | -24.13% |
| 2024 | Skr211.51 Million | +3.62% |
| 2023 | Skr204.11 Million | -29.82% |
| 2022 | Skr290.86 Million | -11.08% |
| 2021 | Skr327.09 Million | -66.96% |
| 2020 | Skr989.94 Million | +133.17% |
| 2019 | Skr424.55 Million | +18.18% |
| 2018 | Skr359.24 Million | +13.09% |
| 2017 | Skr317.65 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of XSpray Pharma AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $59.70 Million USD |
| MoneyControl | $59.70 Million USD |
| MarketWatch | $59.70 Million USD |
| marketcap.company | $59.70 Million USD |
| Reuters | $59.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About XSpray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the tr… Read more